Agreement to Return US$2M to Obsidian
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The cancellation of the associated convertible notes will occur without any additional payments required from Paradigm. The return of these funds will impact Paradigm's available cash and future funding considerations.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Phase 3 Interim Result Below Continuation Threshold
- Suspension from Quotation
- Appendix 4E and 2026 Annual Report
- June 2026 Quarterly Activities Report & Appendix 4C
- Paradigm Receives $5.75m R&D Tax Incentive Refund
Later from Paradigm Biopharmaceuticals
- Continuation of Voluntary Suspension
- Board Initiates Voluntary Administration
- Appointment of Voluntary Administrators
- Continuation of Suspension from Quotation
- PPS Shows Significant Pain Benefit in Rest of World Analysis
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals